MILLER MICHAEL PATRICK
SEC insider (Form 3/4/5 filer). CIK 0001236514. Director at PUMA BIOTECHNOLOGY, INC. (PBYI) and 2 other issuers. 6 reported Form 4/5 transactions since Sep 2024; latest on Jun 11, 2026. Located in LOS ANGELES, CA.
Companies MILLER MICHAEL PATRICK has filed insider reports for
- PUMA BIOTECHNOLOGY, INC. (PBYI): Director
- RIGEL PHARMACEUTICALS INC (RIGL): Director
- BioXcel Therapeutics, Inc. (BTAI): Director
MILLER MICHAEL PATRICK
CIK: 0001236514
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 11, 2026PBYI
PUMA BIOTECHNOLOGY, INC.
AwardDirect27K shares- - May 15, 2026RIGL
RIGEL PHARMACEUTICALS INC
AwardDirect5.8K shares- - Feb 1, 2026RIGL
RIGEL PHARMACEUTICALS INC
AwardDirectStock Option (right to buy)
12K shares- - Jan 9, 2026BTAI
BioXcel Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
17K shares- - Nov 11, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
SaleDirect20K shares at avg. $4.86$97K - Jun 11, 2025PBYI
PUMA BIOTECHNOLOGY, INC.
AwardDirect27K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 11, 2026 |  PBYI PUMA BIOTECHNOLOGY, INC. | Award | 27,000 | - | $0 | Direct |
| May 15, 2026 |  RIGL RIGEL PHARMACEUTICALS INC | Award | 5,750 | - | $0 | Direct |
| Feb 1, 2026 | RIGL RIGEL PHARMACEUTICALS INC | Award Stock Option (right to buy) | 12,000 | - | - | Direct |
| Jan 9, 2026 |  BTAI BioXcel Therapeutics, Inc. | Award Stock Option (Right to Buy) | 17,000 | - | - | Direct |
| Nov 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Sale | 20,000 | $4.86 | $97,228 | Direct |
| Jun 11, 2025 | PBYI PUMA BIOTECHNOLOGY, INC. | Award | 27,000 | - | - | Direct |
1-6 of 6 transactions